SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025

SystImmune, Inc. announced that data from clinical trials evaluating izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjuga...
Home/KnloSights/Clinical Trial Updates/SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025